Investment Thesis
Cadrenal Therapeutics is a pre-revenue clinical-stage pharmaceutical company with deteriorating financial health, burning $3.0M annually in operating cash with only $2.3M in cash reserves, implying less than one year of runway at current burn rate. While the company maintains a debt-free balance sheet with adequate liquidity ratios, the lack of revenue generation, persistent operating losses, and depleting cash position present severe fundamental risk without clear path to profitability or clinical validation milestones.
Strengths
- Debt-free capital structure with zero long-term debt obligations
- Strong liquidity position with current and quick ratios above 2.6x
- Cash represents 79% of total assets, providing some runway for operations
Risks
- Pre-revenue company with zero revenue and operating losses of $2.5M
- Negative operating cash flow of $3.0M with less than 12 months of cash runway at current burn rate
- No visibility into clinical development pipeline, trial status, or catalysts for revenue generation
- Early-stage biotech funding typically requires dilutive capital raises, pressuring existing shareholders
Key Metrics to Watch
- Cash balance relative to quarterly burn rate and runway months remaining
- Clinical trial progress and pipeline advancement toward regulatory approval
- Capital raises or financing announcements and terms (dilution impact)
Financial Metrics
Revenue
N/A
Net Income
-2.5M
EPS (Diluted)
$-1.04
Free Cash Flow
-3.0M
Total Assets
2.9M
Cash
2.3M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-138.9%
ROA
-87.2%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
2.68x
Quick Ratio
2.68x
Debt/Equity
0.00x
Debt/Assets
37.2%
Interest Coverage
-711.48x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T08:59:12.696747 |
Data as of: 2026-03-31 |
Powered by Claude AI